#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4418184	B	Inhibition of NAPRT (unknown origin)	Homo sapiens	22		single protein format	Patent Bioactivity Data
2.	ALA4418185	B	Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor FK866-induced cytotoxicity by measuring reduction in cell viability at 250 uM to 1 mM incubated for 72 hrs by SRB assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data
3.	ALA4418186	B	Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor FK866-induced cytotoxicity by measuring reduction in cell viability at 300 uM to 1 mM incubated for 72 hrs by SRB assay	Homo sapiens	2		cell-based format	Patent Bioactivity Data
4.	ALA4418187	B	Inhibition of NAPRT in human CCRF-CEM cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
5.	ALA4418188	B	Inhibition of NAPRT in human Jurkat cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
6.	ALA4418189	B	Inhibition of NAPRT in human ML2 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
7.	ALA4418190	B	Inhibition of NAPRT in human NOMO cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
8.	ALA4418191	B	Inhibition of NAPRT in human NB4 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
9.	ALA4418192	B	Inhibition of NAPRT in human NAMALWA cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
10.	ALA4418193	B	Inhibition of NAPRT in human Daudi cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
11.	ALA4418194	B	Inhibition of NAPRT in human Raji cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
12.	ALA4418195	B	Inhibition of NAPRT in human ARH77 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
13.	ALA4418196	B	Inhibition of NAPRT in human RPMI8226 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
14.	ALA4418197	B	Inhibition of NAPRT in human U266 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry	Homo sapiens	1		cell-based format	Patent Bioactivity Data
15.	ALA4418200	B	Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor GMX-1778-induced cytotoxicity by measuring reduction in cell viability at 1 mM incubated for 72 hrs by SRB assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data